Considering metabolic reprograming as a hallmark of cancer and the evidence showing that normal cells are less influenced by interventions in the levels of O-GlcNAcylation, is possible to suggest that therapies targeting the O-GlcNAc enzymes, OGT and OGA, or the O-GlcNAcylated form of specific proteins may have therapeutic potential. The gene discussed is OGA; the disease is cancer.